HAYWARD, Calif., May 17, 2017 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced thatPaul Bisaro, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Wednesday, May 24, 2017 at 10:30 a.m. Eastern Time.
About Impax Laboratories, Inc.Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
For more information, please visit the Company's Web site at: www.impaxlabs.com.
Company Contact: Mark DonohueInvestor Relations and Corporate Communications (215) 558-4526 www.impaxlabs.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-to-present-at-the-ubs-global-healthcare-conference-300459219.html
SOURCE Impax Laboratories, Inc.
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All